Skip to main content

Advertisement

Gastric cancer

Edited by Yun Dai and Li Yan

This series was published in Chinese Journal of Cancer

Gastric cancer ranks the fourth most prevalent malignancy yet it is the second leading cause of cancer-related death. Every year, gastric cancer adds nearly 1 million new cancer cases, and 723,000 or 10% of cancer deaths to the global cancer burden. Approximately, 405,000 or 43% of the new cases and 325,000 or 45% of the deaths are in China, making gastric cancer a particularly challenging malignancy.

This thematic series discusses the molecular classifications of gastric cancer by the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) as well as the implications in personalized therapeutic choices; discusses the evolution of gastric surgery and presents perspectives on surgical techniques in treating gastric cancer; and reviews current and emerging targeted agents as well as immunotherapies in treating gastric cancer. With these advancements in molecular characterization, surgical intervention, and targeted and immunotherapies, gastric cancer will enter a personalized medicine era in the next 5 years.

  1. Review

    Gastric cancer: current and evolving treatment landscape

    Gastric (including gastroesophageal junction) cancer is the third leading cause of cancer-related death in the world. In China, an estimated 420,000 patients were diagnosed with gastric cancer in 2011, ranking...

    Weijing Sun and Li Yan

    Chinese Journal of Cancer 2016 35:83

    Published on: 31 August 2016

  2. Editorial

    The journey of personalizing gastric cancer treatment

    Gastric cancer ranks the fourth most prevalent malignancy yet it is the second leading cause of cancer-related death. Every year, gastric cancer adds nearly 1 million new cancer cases, and 723,000 or 10% of ca...

    Li Yan

    Chinese Journal of Cancer 2016 35:84

    Published on: 31 August 2016

  3. Review

    Evolution of gastric surgery techniques and outcomes

    Surgical management of gastric cancer improves survival. However, for some time, surgeons have had diverse opinions about the extent of gastrectomy. Researchers have conducted many clinical studies, making slo...

    Hironori Shiozaki, Yusuke Shimodaira, Elena Elimova, Roopma Wadhwa, Kazuki Sudo, Kazuto Harada, Jeannelyn S. Estrella, Prajnan Das, Brian Badgwell and Jaffer A. Ajani

    Chinese Journal of Cancer 2016 35:69

    Published on: 26 July 2016

  4. Review

    Genomic alterations and molecular subtypes of gastric cancers in Asians

    Gastric cancer (GC) is a highly heterogenic disease, and it is the second leading cause of cancer death in the world. Common chemotherapies are not very effective for GC, which often presents as an advanced or...

    Xiang S. Ye, Chunping Yu, Amit Aggarwal and Christoph Reinhard

    Chinese Journal of Cancer 2016 35:42

    Published on: 9 May 2016

Advertisement